View Exam | PowerPak

1. Which of the following statements is correct regarding PD-1 blockade as an anti-cancer mechanism in the context of immune response?

A. PD-1 blockade leads to T-cell activation and occurs during the priming phase B. PD-1 blockade leads to T-cell activation and occurs during the effector phase C. PD-1 blockade leads to cytokine-based stimulation of the immune system D. PD-1 blockade mimics CTLA-4 pathway inhibition and allows for dual T-cell activation during the priming phase

2. Which of the following is one of the more common immune-related adverse events associated with immune checkpoint blockade in the cancer setting?

A. Alopecia B. Thrombocytopenia C. Enterocolitis D. Venous thromboembolism

3. You are counseling a patient with stage IV melanoma who is experiencing immune-related pneumonitis on therapy with an anti-PD1 antibody (assume dyspnea on exertion but no other symptoms). The patient asks what can be done to manage this toxicity; how would you respond?

A. Recommend discontinuing therapy B. Suggest continued therapy at a lower dose C. Recommend an immunosuppressive agent D. Recommend holding therapy and initiating a course of antibiotics/steroids

4. Which of the following patients would you select as the most appropriate candidate to receive novel immunotherapy with an anti-PD1 antibody?

A. A patient with aggressive, stage IV BRAF+ melanoma B. A patient with advanced NSCLC and a history of Crohn's disease C. A patient with indolent, stage IV BRAF+ melanoma D. A patient with rapidly progressive, relapsed bladder cancer

5. Which statement accurately summarizes the response outcomes from a phase 3 study testing the anti-PD-1 agent nivolumab vs investigator's choice chemotherapy (ICC) in patients with metastatic melanoma?

A. No differences in response were noted between the two regimens B. Nivolumab was associated with a substantially higher response rate compared with ICC C. Nivolumab was associated with a minimally increased response rate compared with ICC D. Nivolumab was associated with a lower response rate compared with ICC

6. Assume a patient with NSCLC is preparing to receive an anti-PD-1 antibody; she asks if she can expect her tumor to shrink rapidly once therapy begins. How would you respond?

A. Admit that it is difficult to predict how a given tumor will respond and that speculating would be unhelpful B. Advise her that rapid tumor shrinkage is expected and that tumor lysis may occur C. Explain that responses may be unconventional and that her tumor may not shrink immediately D. Explain that responses will be similar to what might be expected with a platinum-based chemotherapy regimen

7. Your patient with previously treated advanced NSCLC is preparing to enter a clinical trial testing an anti-PD-1 agent. During a discussion of IRAEs, he expresses confusion about what to do if he experiences toxicity. How would you respond?

A. Explain that it is unlikely he will experience any toxicity B. Offer additional education on IRAEs and encourage rapid reporting of any toxicity C. Suggest treatment with conventional chemotherapy D. Agree that IRAEs are a complicated issue and offer to consider alternative therapy if the patient is not comfortable with his treatment plan

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements is correct regarding PD-1 blockade as an anti-cancer mechanism in the context of immune response?

2. Which of the following is one of the more common immune-related adverse events associated with immune checkpoint blockade in the cancer setting?

3. You are counseling a patient with stage IV melanoma who is experiencing immune-related pneumonitis on therapy with an anti-PD1 antibody (assume dyspnea on exertion but no other symptoms). The patient asks what can be done to manage this toxicity; how would you respond?

4. Which of the following patients would you select as the most appropriate candidate to receive novel immunotherapy with an anti-PD1 antibody?

5. Which statement accurately summarizes the response outcomes from a phase 3 study testing the anti-PD-1 agent nivolumab vs investigator's choice chemotherapy (ICC) in patients with metastatic melanoma?

6. Assume a patient with NSCLC is preparing to receive an anti-PD-1 antibody; she asks if she can expect her tumor to shrink rapidly once therapy begins. How would you respond?

7. Your patient with previously treated advanced NSCLC is preparing to enter a clinical trial testing an anti-PD-1 agent. During a discussion of IRAEs, he expresses confusion about what to do if he experiences toxicity. How would you respond?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements is correct regarding PD-1 blockade as an anti-cancer mechanism in the context of immune response?

2. Which of the following is one of the more common immune-related adverse events associated with immune checkpoint blockade in the cancer setting?

3. You are counseling a patient with stage IV melanoma who is experiencing immune-related pneumonitis on therapy with an anti-PD1 antibody (assume dyspnea on exertion but no other symptoms). The patient asks what can be done to manage this toxicity; how would you respond?

4. Which of the following patients would you select as the most appropriate candidate to receive novel immunotherapy with an anti-PD1 antibody?

5. Which statement accurately summarizes the response outcomes from a phase 3 study testing the anti-PD-1 agent nivolumab vs investigator's choice chemotherapy (ICC) in patients with metastatic melanoma?

6. Assume a patient with NSCLC is preparing to receive an anti-PD-1 antibody; she asks if she can expect her tumor to shrink rapidly once therapy begins. How would you respond?

7. Your patient with previously treated advanced NSCLC is preparing to enter a clinical trial testing an anti-PD-1 agent. During a discussion of IRAEs, he expresses confusion about what to do if he experiences toxicity. How would you respond?

« Return to Activity

Customers who Purchased
this Activity also Purchased